Epigenetic disruption of cadherin-11 in human cancer metastasis

Little is known about the molecular events occurring in the metastases of human tumours. Epigenetic alterations are dynamic lesions that change over the natural course of the disease, and so they might play a role in the biology of cancer cells that have departed from the primary tumour. Herein, we...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of pathology Vol. 228; no. 2; pp. 230 - 240
Main Authors Carmona, F. Javier, Villanueva, Alberto, Vidal, August, Muñoz, Clara, Puertas, Sara, Penin, Rosa M, Gomà, Montserrat, Lujambio, Amaia, Piulats, Josep M, Mesía, Ricard, Sánchez-Céspedes, Montse, Manós, Manel, Condom, Enric, Eccles, Suzanne A, Esteller, Manel
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.10.2012
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Little is known about the molecular events occurring in the metastases of human tumours. Epigenetic alterations are dynamic lesions that change over the natural course of the disease, and so they might play a role in the biology of cancer cells that have departed from the primary tumour. Herein, we have adopted an epigenomic approach to identify some of these changes. Using a DNA methylation microarray platform to compare paired primary tumour and lymph node metastatic cell lines from the same patient, we observed cadherin‐11 promoter CpG island hypermethylation as a likely target of the process. We found that CDH11 DNA methylation‐associated transcriptional silencing occurred in the corresponding lymph node metastases of melanoma and head and neck cancer cells but not in the primary tumours. Using in vitro and in vivo cellular and mouse models for depleted or enhanced CDH11 activity, we also demonstrated that CDH11 acts as an inhibitor of tumour growth, motility and dissemination. Most importantly, the study of CDH11 5′‐CpG island hypermethylation in primary tumours and lymph node metastases of cancer patients showed this epigenetic alteration to be significantly confined to the disseminated cells. Overall, these results indicate the existence of metastasis‐specific epigenetic events that might contribute to the progression of the disease. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Bibliography:ArticleID:PATH4011
istex:BCD836E31A99CE5CFEF775E7F9185E6BFA4FFC66
ark:/67375/WNG-KB7XRZ1G-6
Supporting Information: Figure S1. Bisulphite genomic sequencing of paired primary/metastasis clinical samples.Supporting Information: Legends to Figure S1
No conflicts of interest were declared.
Re-use of this article is permitted in accordance with the Terms and Conditions set out at . [http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms]
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms.
ISSN:0022-3417
1096-9896
DOI:10.1002/path.4011